genes

MAPT

MAPT encodes tau, a microtubule-associated protein that stabilizes axonal transport and neuronal polarity. Hyperphosphorylated tau can detach from microtubules and aggregate into neurofibrillary tangles, a major pathology in Alzheimer disease and primary tauopathies.

schedule 10 min read update Updated February 28, 2026

Key Takeaways

  • MAPT encodes tau, a microtubule-associated protein that stabilizes axonal microtubules and supports transport.
  • Hyperphosphorylated tau can detach from microtubules, mislocalize, and aggregate into neurofibrillary tangles.
  • MAPT mutations cause inherited tauopathies such as FTDP-17, and common haplotypes influence PSP and CBD risk.
  • Tau pathology correlates strongly with cognitive decline in Alzheimer disease and can spread in a prion-like manner.

Basic Information

Gene Symbol
MAPT
Full Name
Microtubule Associated Protein Tau
Also Known As
TauFTDP-17MAPTL
Location
17q21.31
Protein Type
Microtubule-associated protein
Protein Family
MAP family

Related Isoforms

Key SNPs

rs1052553 3' region

Classic marker distinguishing the MAPT H1 and H2 haplotypes; H1 is associated with increased PSP and CBD risk.

rs1800547 Inversion haplotype

Haplotype-linked variant used in studies of tauopathies and neurodegenerative disease risk.

rs242557 Intronic

Variant in the H1c sub-haplotype, associated with altered MAPT expression and tauopathy risk.

rs2471738 Intronic

H1-related locus used in association studies; may tag regulatory variation influencing MAPT expression.

rs7521 3' UTR

Variant in the MAPT region used to tag haplotype structure and expression quantitative trait loci.

rs63751273 Exonic (P301L)

Pathogenic MAPT mutation that promotes tau aggregation and causes autosomal-dominant FTDP-17.

rs63750424 Exonic (N279K)

Splicing-affecting mutation that increases 4R tau isoforms and is linked to familial tauopathy.

Overview

MAPT encodes tau, a microtubule-associated protein that stabilizes microtubules in axons and supports long-range transport of mitochondria, vesicles, and synaptic cargo. Tau function depends on a delicate balance of phosphorylation and binding to microtubules, which shifts with development, neuronal activity, and cellular stress.

Tau pathology begins when tau becomes excessively phosphorylated, detaches from microtubules, and mislocalizes from axons into the soma and dendrites. Mislocalized tau can form oligomeric seeds and fibrils that assemble into neurofibrillary tangles. In Alzheimer disease and other tauopathies, tau burden correlates strongly with clinical decline.

Conceptual Model

A simplified mental model for the pathway:

Tau
Healthy state
Microtubule binding
p-Tau
Detachment
Mislocalization
Seed
Aggregation
Template spread
Tangle
End state
Circuit failure

Oligomeric and seeding-competent tau species can be more directly toxic than large, late-stage inclusions.

Core Health Impacts

  • Axonal stability: Stabilizes axonal microtubules and supports long-range transport.
  • Neuronal polarity: Coordinates neuronal polarity by maintaining axon structure and trafficking.
  • Signaling tuning: Phosphorylation state tunes microtubule binding and localization.
  • Synaptic health: Pathological aggregation disrupts synapses and activates glial stress responses.
  • Cognitive tracking: Tangle burden correlates strongly with cognitive decline in Alzheimer disease.

Protein Domains

N-terminal projection

Extends away from microtubules and influences spacing, interactions, and localization.

Proline-rich region

Contains many phosphorylation sites; kinase-phosphatase balance here influences detachment.

Binding repeats

Repeat domains bind microtubules; mutations here affect 3R and 4R isoform aggregation.

Upstream Regulators

GSK3β Activator

Major tau kinase that phosphorylates tau at multiple sites, increasing aggregation propensity.

CDK5 Activator

Stress-driven dysregulation can increase tau phosphorylation and contribute to neurodegeneration.

PP2A Inhibitor

Major tau phosphatase; reduced activity increases net tau phosphorylation.

Amyloid-beta Activator

Upstream amyloid pathology can activate kinase cascades that promote tau spread.

Neuroinflammation Activator

Cytokines and microglial activation can promote tau pathology.

Autophagy Inhibitor

Aging-related decline in autophagy reduces clearance of misfolded tau species.

Downstream Targets

Microtubules Activates

Tau binds and stabilizes microtubules in axons; hyperphosphorylation reduces binding.

Axonal transport Activates

Loss of microtubule integrity disrupts trafficking of mitochondria and synaptic components.

Synapses Inhibits

Mislocalized tau can accumulate in dendrites and synapses, impairing plasticity.

Neurofibrillary tangles Activates

Aggregated tau forms paired helical filaments and tangles linked to clinical decline.

Glia Activates

Extracellular tau species can activate glia and propagate inflammation.

Apoptosis Activates

Downstream responses to tau aggregation include mitochondrial dysfunction and cell death.

Role in Aging

Aging is the strongest risk factor for tau pathology. With age, kinase and phosphatase balance can drift, axonal transport weakens, and clearance pathways decline.

Kinase drift

Aging can shift signaling toward higher net phosphorylation, increasing the probability of tau detachment from microtubules.

Transport decline

Weaker axonal transport reduces delivery of mitochondria and synaptic cargo, increasing vulnerability of long projection neurons.

Autophagy decline

Reduced lysosomal function and autophagy capacity limit clearance of misfolded tau and can increase the lifetime of seeds.

Sleep and clearance

Poor sleep and reduced glymphatic flux may increase persistence of extracellular tau species and inflammatory signaling.

Inflammaging

Chronic low-grade inflammation lowers the threshold for glial activation and can accelerate tau spread.

Vascular vulnerability

Small vessel disease and blood-brain barrier changes can interact with tau pathology and worsen cognitive trajectories.

Disorders & Diseases

Alzheimer Disease

Tau tangles and tau burden correlate strongly with cognitive decline in AD. Tau spread is closely linked to symptom severity.

Braak staging: Anatomic progression of tau pathology
p-Tau markers: Track disease biology and progression

FTDP-17

Pathogenic MAPT mutations cause autosomal-dominant frontotemporal dementia with parkinsonism.

Progressive Supranuclear Palsy

A primary 4R tauopathy characterized by postural instability. The MAPT H1 haplotype increases risk.

Corticobasal Degeneration

A 4R tauopathy with asymmetric motor features. MAPT region variation influences risk.

CTE

Repetitive head impacts are associated with tau pathology in characteristic cortical patterns.

Interventions

Supplements

Omega-3 fatty acids

Support synaptic membranes and may reduce neuroinflammatory tone that can amplify tau pathology.

Curcumin

Polyphenol studied for anti-aggregation and anti-inflammatory effects relevant to amyloid.

EGCG

Green tea catechins studied for potential inhibition of protein aggregation.

Magnesium

Supports sleep quality and excitability balance, indirectly supporting cognitive resilience.

Vitamin D

Immune-modulating hormone with associations to cognition and inflammation control.

Lifestyle

Aerobic exercise

Supports vascular health and reduces inflammatory burden, which can influence neurodegeneration.

Sleep optimization

Sleep supports waste clearance and may reduce net accumulation of aggregation-prone tau species.

Cardiometabolic control

Managing blood pressure, glucose, and lipids reduces vascular contributions to cognitive impairment.

Cognitive engagement

Builds cognitive reserve and can delay functional impact even when pathology is present.

Medicines

Anti-tau antibodies

Experimental immunotherapies designed to bind extracellular tau species and reduce spread.

Tau inhibitors

Investigational agents aimed at reducing fibril formation and seeding of tau assemblies.

Anti-amyloid therapies

In Alzheimer disease, reducing amyloid may lower kinase pressure that accelerates tau spread.

Donepezil

Cholinesterase inhibitor used for symptomatic support of cognition in Alzheimer disease.

Lab Tests & Biomarkers

Genetic Testing

MAPT sequencing

Clinical sequencing identifies pathogenic mutations linked to inherited tauopathies like FTDP-17.

Haplotype markers

Common MAPT haplotypes (H1/H2) influence risk for primary tauopathies such as PSP and CBD.

Fluid Biomarkers

Plasma p-Tau

Phosphorylated tau species in blood track Alzheimer-related tau biology early in disease.

CSF total/p-tau

CSF tau measures can reflect neurodegeneration and tau phosphorylation state.

Plasma NfL

Non-specific marker of axonal injury, useful for tracking rate of neurodegeneration.

Imaging

Tau PET

PET ligands can visualize tau burden in vivo, helping stage disease biology.

Structural MRI

Regional atrophy patterns can suggest tauopathy subtype and track progression.

Hormonal Interactions

Estrogen Neuroprotective

May influence kinase signaling and synaptic resilience, intersecting with tau pathology.

Cortisol Stress Factor

Chronic elevation can worsen sleep and amplify neuroinflammatory signaling.

Insulin Metabolic Link

Brain insulin resistance is associated with impaired proteostasis and tau phosphorylation.

Melatonin Circadian Lead

Supports sleep architecture, which is linked to brain clearance and resilience.

Deep Dive

Network Diagrams

Tau Detachment and Aggregation

Tau Seeding and Network Spread

Biological Role: From Microtubule Binding to Tangle

Tau normally stabilizes microtubules in axons. Pathology emerges when tau becomes excessively phosphorylated, detaches from microtubules, and mislocalizes into compartments where it can form oligomers and fibrils.

Detachment: Kinase activation (such as GSK3β) and reduced phosphatase activity increase net phosphorylation, weakening tau microtubule binding.

Mislocalization: Tau shifts from axons into the soma and dendrites, disrupting synapses and local signaling.

Seeding and fibrils: Oligomeric tau species can seed additional tau, forming fibrils that accumulate as neurofibrillary tangles.

Seeding and Spread Through Neural Circuits

Misfolded tau can move between connected neurons. Once internalized, tau seeds can template further misfolding and propagate pathology along networks that support memory and executive function.

Release and uptake: Tau species can be released to extracellular space and taken up by neighboring cells via endocytosis and other mechanisms.

Template amplification: Seed-competent tau assemblies can accelerate misfolding of soluble tau in recipient cells, supporting network-level progression.

Isoforms and Splicing: 3R and 4R Tau

MAPT produces multiple tau isoforms through alternative splicing. A key axis is the balance between 3-repeat and 4-repeat microtubule-binding domains. Several FTDP-17 mutations alter splicing, shifting the 3R to 4R ratio and increasing aggregation propensity.

Different tauopathies have characteristic isoform compositions and filament structures, which may explain differences in regional vulnerability and clinical phenotypes.

Relevant Research Papers

Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.

Grundke-Iqbal et al. (1986) PNAS
PubMed Free article DOI

Early evidence that tau is a core component of neurofibrillary tangles.

Hutton et al. (1998) Nature

Landmark paper linking MAPT mutations to familial frontotemporal dementia.

Fitzpatrick et al. (2017) Nature

Resolved the core fold of tau filaments in Alzheimer disease.

Clavaguera et al. (2009) Nature Cell Biology

Evidence for prion-like spreading of tau pathology in vivo.